Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTC299 in HIV-Related Kaposi's Sarcoma
NCT00686842Phase 2Terminated
- Sponsor
- AIDS Malignancy Consortium
- Start
- Sep 2008
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of emvododstat in Kaposi sarcoma (KS), sponsored by AIDS Malignancy Consortium. Primary endpoints: Safety and Toxicity of Anti-VEGF Small Molecule PTC299, Maximum Tolerated Dose and 1 more. Started Sep 2008; status: terminated.
02
Drugs
emvododstat
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT00686842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00686842.